Want to accelerate your biomarker development towards the clinic?

In the era of personalised medicine, biomarkers play a crucial role in diagnostic and treatment decisions, and represent a key strategy for innovative clinical trials that will facilitate cost-effective and speedy assessment of new drugs for efficacy and market approval.

The EATRIS Biomarkers Platform facilitates the validation and development of biomarkers for the prevention, diagnosis and prognostic assessment of disease as well as for the prediction of therapy response.

What can EATRIS offer the biomarker developer?

- 1. 80+ European biomarker development centres
- 2. Personalised medicine focus
- 3. Access to a range of cutting-edge scientific, technological, clinical and regulatory expertise
 - 4. Access to biobanks and patients' datasets
 - 5. Assay development and validation
 - 6. Multi-centre clinical trials

What services can we provide?

Multi-omics Single-cell technologies <u>immunoprofiling</u> Digital diagnostics: Imaging biomarkers, radiomics Liquid biopsy Multimodal biomarkers Pre-clinical in vivo validation in disease Advanced profiling of Tissue-based specific animal patient-derived biomarkers models including preclinical models Access to biobank Access to medical Testing and samples (e.g. data and clinical comparison of tissues, cells, DNA, experts and IVD biomarker assays; regulatory services assay development - Scientific advice and validation

Looking for something else?

Contact Emanuela Oldoni, Scientific Programme Manager: emanuelaoldoni@eatris.eu

Or find us online:

eatris.eu
EatrisEric in eatris-eric ► EATRIS-ERIC EATRIS.ERIC